Applications of Liver Humanized Mouse Models in Preclinical Drug Development, Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, the featured speaker will discuss the major liver humanized mouse models currently available and give numerous examples of how humanized mice have been successfully used as disease models, to address DMPK concerns and as a unique method to study human liver toxicity. Attendees will gain an understanding of how these models may fit into their drug discovery and development process.

Xtalks Logo

Xtalks Life Science Webinars

Over the past two decades, much progress has been made in the development of mouse models which are able to achieve at least 70% replacement of mouse hepatocytes with human hepatocytes.

Animal models are traditionally used in the drug development process to determine the safety and efficacy of new drug candidates. Yet, translation between animals and humans is not always straightforward due to inherent differences between species. A promising way to bridge this gap has been the development of chimeric mice possessing humanized livers. Over the past two decades, much progress has been made in the development of mouse models which are able to achieve at least 70% replacement of mouse hepatocytes with human hepatocytes. This has enabled the use of these models for an increasing variety of applications in the preclinical drug development process.

The first segment of this webinar will focus on the genetic basis of these liver-humanized mouse models, as well as their historical development and characterization. The second and major segment of the presentation will illustrate their use in a wide variety of in vivo and in vitro applications over the past decade. These include liver disease models such as hepatitis B and C virus infection. Numerous publications have described the use of liver-humanized mouse models for studies on drug metabolism and pharmacokinetics, enzyme induction, drug clearance projections, identification of human metabolites and the prediction of clinically relevant drug-drug interactions. Liver toxicity studies have been carried out both in vivo and in vitro, the latter utilizing hepatocytes isolated from these liver humanized mice. Finally, these models are useful to test the delivery of gene therapy reagents to the liver, as well as to repopulate the liver with genetically modified hepatocytes.

Join David Thompson, Ph.D., Sr. Director, Mechanistic Pharmacology & Toxicology, Inotiv in a live webinar on Thursday, October 15, 2020 at 1pm EDT.

For more information or to register for this event, visit Applications of Liver Humanized Mouse Models in Preclinical Drug Development.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sydney Perelmutter
Xtalks
+1 (416) 977-6555 x 352
Email >
Visit website